NICE yes for Roche's Herceptin
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is U-turning on earlier draft guidance that turned down Roche's HER2-targeted anticancer Herceptin (trastuzumab) for patients with metastatic gastric cancer. Thanks to a new analysis on a subgroup of patients with high HER2 levels, the institute said today in final draft guidance that the drug can be used on the NHS.